Business
Rallybio Reports First Quarter 2022 Financial Results
-- Initiated Phase 1b proof-of-concept study for RLYB212 for the prevention of FNAIT; initial data expected in 3Q 2022 -- -- Phase 1 study of RLYB116
About this update from Rallybio Corporation
[{"type":"text","content":"\n-- Initiated Phase 1b proof-of-concept study for RLYB212 for the prevention of FNAIT; initial data expected in 3Q 2022 --\n\n-- Phase 1 study of RLYB116 ongoing; initial single dose safety, PK, and PD data expected in 2H 2022 --\n\n-- Acquired RLYB331 from Sanofi, a potentially first-in-class antibody for the treatment of multiple severe anemias with ineffective erythropoiesis and iron overload --\n\n NEW HAVEN, Conn.--(BUSINESS WIRE)--\nRallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the first quarter ended March 31, 2022 and provided an update on recent program and corporate developments.\n\n“We continue to move forward with our mission of discovering, developing, manufacturing and delivering therapies that meaningfully improve the lives of people with devastating rare diseases,” said Martin Mackay, Ph.D., Chief Executive Officer of Rallybio. “We announced this morning that we completed our first acquisition as a public company, in-licensing RLYB331, a highly differentiated product candidate that could transform the treatment of severe, non-malignant hematological disorders. This transaction is an excellent example of our strategy of expanding our pipeline by investing in assets that have a clear mechanism of action, address a significant unmet patient need, and are complementary to our existing portfolio.”\n\nDr. Mackay continued, “In parallel, we advanced our two clinical-stage programs, RLYB212 and RLYB116. We are pleased to announce today the initiation of the Phase 1b proof-of-concept study of RLYB212, which is designed to establish the ability of RLYB212 to rapidly eliminate transfused HPA-1a positive platelets from HPA-1a negative healthy subjects. We look forward to reporting data from this study, as well as our ongoing Phase 1 study of RLYB116, later this year.”\n\nRecent Business Highlights and Upcoming Milestones:\n\nMaternal Fetal Blood Disorders\n\nIn January 2022, Rallybio announced that the first subjects were dosed in the Phase 1 study of RLYB212, a novel human monoclonal anti-HPA-1a antibody in development for the prevention of FNAIT (fetal and neonatal alloimmune thrombocytopenia). This single-blind, placebo-cont...